- Oral presentation
- Open Access
Development of breast cancer immunotherapy using MUC1-retargeted T lymphocytes
© BioMed Central Ltd 2008
- Published: 13 May 2008
- Breast Cancer
- Chimeric Antigen Receptor
- Bioluminescent Imaging
- Breast Cancer Xenograft
- Rapid Tumour Growth
MUC1 is a highly attractive target for immunotherapy of breast cancer owing to its overexpression, altered glycosylation and loss of polarity in over 90% of tumours. To exploit this, we are developing genetic approaches to retarget T-cell specificity to MUC1 using chimeric antigen receptor (CAR) technology.
A panel of CARs have been generated using scFv derived from the SM3 and HMFG2 hybridomas. Using the SFG oncoretroviral expression vector, gene transfer was achieved in up to 75% of human T cells.
Despite its role in tumorigenesis and immune evasion, we show that the near-ubiquitous breast cancer antigen MUC1 can be targeted using CAR grafted T cells.
Supported by a Health Foundation/Royal College of Pathologists Senior Clinician Scientist Research Fellowship and a Project Grant awarded by Breast Cancer Campaign.